Altimmune to Participate in Upcoming Investor Conferences
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on peptide-based therapeutics for liver and cardiometabolic diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will attend the Wells Fargo Healthcare Conference in Boston on September 5 for one-on-one meetings, the H.C. Wainwright Global Investment Conference in New York on September 9 with a fireside chat at 8:30 a.m. ET, and the Morgan Stanley Global Healthcare Conference in New York on September 10 with a fireside chat at 7:45 a.m. ET. The fireside chat sessions will be available via webcast on Altimmune's website.
Altimmune (NASDAQ:ALT), azienda biofarmaceutica in fase clinica avanzata specializzata in terapie peptidiche per malattie epatiche e cardiometaboliche, ha annunciato la sua partecipazione a tre conferenze per investitori previste per settembre 2025.
La società sarà presente al Wells Fargo Healthcare Conference a Boston il 5 settembre per incontri one-to-one, al H.C. Wainwright Global Investment Conference a New York il 9 settembre con un fireside chat alle 8:30 ET e al Morgan Stanley Global Healthcare Conference a New York il 10 settembre con un fireside chat alle 7:45 ET. Le sessioni di fireside chat saranno trasmesse in webcast sul sito web di Altimmune.
Altimmune (NASDAQ:ALT), una compañía biofarmacéutica en fase clínica avanzada centrada en terapias peptídicas para enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en tres conferencias para inversores en septiembre de 2025.
La empresa asistirá al Wells Fargo Healthcare Conference en Boston el 5 de septiembre para reuniones one-on-one, al H.C. Wainwright Global Investment Conference en Nueva York el 9 de septiembre con un fireside chat a las 8:30 a. m. ET, y al Morgan Stanley Global Healthcare Conference en Nueva York el 10 de septiembre con un fireside chat a las 7:45 a. m. ET. Las sesiones de fireside chat estarán disponibles por webcast en la web de Altimmune.
Altimmune (NASDAQ:ALT)는 간 및 심장대사 질환을 위한 펩타이드 기반 치료제를 개발하는 후기 임상 단계의 바이오제약사로, 2025년 9월 예정된 세 건의 투자자 컨퍼런스에 참가한다고 발표했습니다.
회사는 9월 5일 보스턴에서 열리는 Wells Fargo Healthcare Conference에서 1:1 미팅을 진행하고, 9월 9일 뉴욕에서 열리는 H.C. Wainwright Global Investment Conference에서는 동부시간 오전 8시 30분에 fireside chat을, 9월 10일 뉴욕의 Morgan Stanley Global Healthcare Conference에서는 동부시간 오전 7시 45분에 fireside chat을 진행합니다. fireside chat 세션은 Altimmune 웹사이트를 통해 웹캐스트로 시청할 수 있습니다.
Altimmune (NASDAQ:ALT), une société biopharmaceutique en phase clinique avancée spécialisée dans les thérapeutiques peptidiques pour les maladies hépatiques et cardiométaboliques, a annoncé sa participation à trois conférences investisseurs prévues en septembre 2025.
La société participera au Wells Fargo Healthcare Conference à Boston le 5 septembre pour des réunions en tête‑à‑tête, au H.C. Wainwright Global Investment Conference à New York le 9 septembre avec un fireside chat à 8h30 ET, et au Morgan Stanley Global Healthcare Conference à New York le 10 septembre avec un fireside chat à 7h45 ET. Les sessions de fireside chat seront accessibles par webcast sur le site d'Altimmune.
Altimmune (NASDAQ:ALT), ein biopharmazeutisches Unternehmen in späten klinischen Phasen, das sich auf peptidbasierte Therapeutika für Leber- und kardiometabolische Erkrankungen spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen im September 2025 angekündigt.
Das Unternehmen wird am 5. September auf der Wells Fargo Healthcare Conference in Boston für Einzelgespräche vertreten sein, am 9. September in New York auf der H.C. Wainwright Global Investment Conference mit einem Fireside-Chat um 8:30 Uhr ET und am 10. September in New York auf der Morgan Stanley Global Healthcare Conference mit einem Fireside-Chat um 7:45 Uhr ET. Die Fireside-Chat-Sitzungen werden per Webcast auf der Website von Altimmune verfügbar sein.
- None.
- None.
GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:
- Wells Fargo Healthcare Conference in Boston, MA
Friday, September 5, 2025
One-on-one meetings only
- H.C. Wainwright Global Investment Conference in New York, NY
Tuesday, September 9, 2025
Fireside chat at 8:30 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
- Morgan Stanley Global Healthcare Conference in New York, NY
Wednesday, September 10, 2025
Fireside chat at 7:45 a.m. Eastern Time
The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Media Contact:
Jake Robison
Inizio Evoke Comms
Phone: 619-849-5383
jake.robison@inizioevoke.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the H.C. Wainwright Global Investment Conference 2025?
Where can I watch Altimmune's (ALT) presentations at the September 2025 investor conferences?
What type of company is Altimmune (ALT)?
Which investor conferences is Altimmune (ALT) attending in September 2025?
